Triple Peptide Vaccine

Chicago - Data involving the first 60 patients in a phase II clinical trial of a multi-epitope peptide vaccination, as combined with other agents, showed a median survival of 21 months for immunological responders as compared to 13 months in immunologic nonresponders.

Related Videos
Related Content

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

Advancements in Understanding the Skin's Microbiomes

March 20th 2023

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

Advancements in Understanding the Skin's Microbiomes

March 20th 2023

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

Advancements in Understanding the Skin's Microbiomes

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.